EP3244834B1 - Mitral bileaflet valve - Google Patents
Mitral bileaflet valve Download PDFInfo
- Publication number
- EP3244834B1 EP3244834B1 EP15878296.1A EP15878296A EP3244834B1 EP 3244834 B1 EP3244834 B1 EP 3244834B1 EP 15878296 A EP15878296 A EP 15878296A EP 3244834 B1 EP3244834 B1 EP 3244834B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- leaflet
- assembly
- section
- sections
- annulus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002837 heart atrium Anatomy 0.000 claims description 18
- 210000003709 heart valve Anatomy 0.000 claims description 11
- 230000007704 transition Effects 0.000 claims description 11
- 230000017531 blood circulation Effects 0.000 claims description 8
- 210000004115 mitral valve Anatomy 0.000 description 32
- 210000001765 aortic valve Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- -1 NitinolTM Inorganic materials 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/2436—Deployment by retracting a sheath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
- A61F2220/0075—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0008—Rounded shapes, e.g. with rounded corners elliptical or oval
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0034—D-shaped
Definitions
- the present disclosure is directed to methods, systems, and apparatus for safely replacing or repairing native heart valves with prosthetic heart valves.
- Prosthetic heart valves have been used for many years to treat cardiac valvular disorders.
- the native heart valves (such as the aortic, pulmonary, and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system.
- These heart valves can be rendered less effective by congenital, inflammatory, or infectious conditions. Such conditions can eventually lead to serious cardiovascular compromise or death.
- the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery, but such surgeries are dangerous and prone to complication.
- Typical prosthetic heart valves are known in the art, for example, patent application publication No. US2013317603A1 discloses devices and methods for implantation at a native mitral valve having a non-circular annulus and leaflets.
- Patent application publication No. US2010280606A1 discloses a valve prosthesis adapted to operate in conjunction with native heart valve leaflets, which includes an annulus and a skirt extending from the annulus.
- Patent application publication No. US2004122513A1 discloses a stentless bioprosthetic valve which includes at least one piece of biocompatible material comprising a bi-leaflet conduit having a proximal end and a distal end.
- a transvascular technique for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery.
- a prosthetic valve is mounted in a crimped state on the end portion of a flexible catheter and advanced through a blood vessel of the patient until the valve reaches the implantation site.
- the valve at the catheter tip is then expanded to its functional size at the site of the defective native valve, such as by inflating a balloon on which the valve is mounted.
- the valve can have a resilient, self-expanding stent or frame that expands the valve to its functional size when it is advanced from a delivery sheath at the distal end of the catheter.
- the mitral valve annulus does not provide a good landmark for positioning a replacement mitral valve.
- the height and width of the aortic annulus are generally increased in the presence of degenerative disease associated with calcium formation. These changes in tissue make it easier to properly secure a replacement aortic valve in place due to the reduced cross-sectional area of the aortic annulus.
- the degenerative changes typically found in aortic valves are not, however, present in mitral valves experiencing regurgitation, and a mitral valve annulus is therefore generally thinner than the annulus of a diseased aortic valve.
- the thinner mitral valve annulus makes it relatively more difficult to properly seat a replacement mitral valve in the native mitral valve annulus.
- the general anatomy of the mitral valve annulus also makes it more difficult to properly anchor a replacement mitral valve in place.
- the mitral valve annulus provides for a smoother transition from the left atrium to the left ventricle than the transition that the aortic valve annulus provides from the aorta to the left ventricle.
- the aortic annulus is anatomically more pronounced, providing a larger "bump" to which a replacement aortic valve can more easily be secured in place.
- the larger mitral valve annulus makes it difficult to securely implant current percutaneously delivered valves in the native mitral position.
- a replacement mitral valve that has a valve support structure or anchoring device that can be positioned near or within the native mitral valve.
- the present invention provides a heart valve assembly that has a leaflet support structure and a leaflet assembly.
- the leaflet support structure has a wire frame having an anterior atrium annulus section and a posterior atrium annulus section, with each opposite end of the atrium annulus sections transitioning to a commissure section that curves radially inwardly along the same plane as the atrium annulus sections.
- Each commissure section transitions via a first bend to a leg which extends vertically at opposite central points of the wire frame.
- Each leg extends vertically and slightly radially outwardly at an angle, and each leg transitions via a second bend which extends radially outwardly and transitions into a tail that extends vertically upwardly, with a gap defined between each corresponding tail and leg.
- the leaflet assembly has first and second separate leaflets, each of which is comprised of a skirt section and a sinus leaflet section.
- Each skirt section has a flange portion and a body portion that has a smaller diameter than the flange portion, with the body portion having opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion.
- Each sinus leaflet section has an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges.
- the opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet.
- the flange portion has an inflow edge, and a blood flow lumen is defined by the skirt sections and sinus leaflet sections of the first and second leaflets, with the blood flow lumen extending from the inflow edges of the skirt sections to the outflow edges of the sinus leaflet sections.
- the present invention provides a mitral valve device 100 that is shown in fully assembled form in FIG. 1 .
- the device 100 has a wire frame 102 (see FIGS. 2A-2C ) that is adapted to carry an integrated leaflet assembly 104 (see FIGS. 3A-4D ).
- the wire frame 102 provides a simple leaflet valve support structure that can be effectively secured at the native mitral valve annulus.
- the leaflet assembly 104 provides a novel leaflet configuration which provides fast opening and closing of the valve leaflets.
- the overall construction of the device 100 is simple, and effective in promoting proper mitral valve function.
- the wire frame 102 comprises an anterior atrium annulus section 7 and a posterior atrium annulus section 8, each of which extends horizontally and is shaped like half an oval.
- a U-shaped extension 19 and 20 is provided at about the central portion of each section 7 and 8, respectively, and extends radially outwardly. These extensions 19 and 20 function to seat the device 100 on the native annulus, and for use in being held by the hooks 191 and 201 of the delivery system (see FIG. 8 ) during percutaneous delivery.
- Each opposite end of the atrium annulus sections 7 and 8 transitions to a commissure section 9 and 10 that curves radially inwardly along the same plane as the atrium annulus sections 7 and 8, and then transitions via bends 11 and 12 to legs 17 and 18 which extend vertically at opposite central points of the wire frame 102.
- Each leg 17 and 18 extends vertically and slightly radially outwardly at an angle (see FIG. 2C ), and transitions via bends 13 and 14, respectively, which extend radially outwardly and transition into tails 131 and 141, respectively, that extend vertically upwardly before terminating at rounded ends 16 and 15, respectively, which curve radially outwardly.
- Gaps G1 and G2 are defined between the tail 131 and the leg 17, and the tail 141 and 18, respectively.
- the wire frame 102 can define an oval shape (when viewed from the top), a circular shape, or a D shape.
- FIGS. 1A and 1B illustrate some exemplary dimensions for the device 100 as follows:
- exemplary dimensions can be used for a device 100 that is adapted for use at the native mitral valve location for a generic adult and these dimensions will vary for devices 100 that are used for other applications, such as for a triscupid valve. These exemplary dimensions illustrate the proportions of the various elements to each other.
- the wire frame 102 can be made of one continuous wire, and can be made from a thin wall biocompatible metallic element (such as stainless steel, Co-Cr based alloy, NitinolTM, Ta, and Ti etc.).
- the wire can be made from a NitinolTM wire that is well-known in the art, and have a diameter of 5.08mm to 10.16mm (0.2" to 0.4").
- the present invention provides a novel leaflet assembly 104 that provides a better coaptation between the leaflets.
- the leaflet assembly 104 provides two separate leaflets, each of which is comprised of an upper skirt section la or 1b, and a lower sinus leaflet section 2a or 2b.
- sections 1a and 2a make up one leaflet
- sections 1b and 2b make up the other leaflet.
- the skirt sections 1a and 1b are identical, and each has a larger-diameter semi-oval flange portion 6a or 6b, and a smaller-diameter body portion 4a or 4b.
- Each body portion 4a or 4b has opposing side edges 26a that function as commissure folding lines along which the side edges 26a may be stitched to assemble the two separate leaflets into a single leaflet assembly 104.
- Each body portion 4a or 4b also has a central U-shaped opening defined by stitching edge 29, which is adapted to receive the curved edge of the corresponding sinus leaflet section 2a or 2b.
- Each skirt section 1a, 1b creates an oval-shaped site on the top of the natural annulus.
- Each sinus leaflet section 2a or 2b has a generally semi-circular shape, including an outflow edge 3a or 3b, and a curved edge defined by stitching edge 31.
- Each sinus leaflet section 2a or 2b is stitched along its stitching edge 31 to the stitching edge 29 of the corresponding body portion 4a or 4b.
- FIG. 6D is a top view of a natural mitral valve with six natural components labeled by A1, A2, A3 and P1, P2, P3.
- FIG. 4A the leaflet assembly 104 has the same six components where 4a, 2a and 4a correspond to A1, A2 and A3, respectively, and 4b, 2b, 4b correspond to P1, P2 and P3, respectively. For this reason, the leaflet assembly 104 is able to function in a manner which comes closest to replicating the natural function of the native mitral valve.
- FIG. 5A illustrates the wire frame 102 used with a conventional bi-leaflet valve assembly where the two leaflets must necessarily be long enough so as to allow for proper coaptation at the outflow end.
- the sinus leaflet sections 2a, 2b can function to provide better leaflet coaptation along its outflow edges 3a, 3b while maintaining a shorter or lower profile. This in turn allows the skirt sections 1a, 1b to have a shorter profile.
- a shorter profile can be important because, if the valve body is too long, it could potentially interfere with the blood flow in the aortic direction.
- FIGS. 3A-4D compare the dimensions in FIGS. 1B using the novel leaflet design of the present invention with the dimensions in FIG. 5A for a conventional bi-leaflet valve assembly.
- the valve design provides a "belly sinus" for a large opening.
- the opening provided by a conventional bi-leaflet valve in FIG. 5A would be L0, which is 28 mm.
- the novel leaflet design of the present invention allows the valve to open and close faster because a valve with a shorter profile and having the sinus 2a, 2b will allow for the valve to open and close completely.
- the leaflet coaptation length will be short when the valve closes, and with the control provided by the body portions 4a, 4b when the valve is closed, this would allow the valve to open more quickly.
- the leaflet coaptation length will be longer for the valve when it is fully closed, which takes too much time and requires greater pressure for the valve to open. Given the fact that a natural mitral valve usually opens at a pressure of 15 mm Hg and closes at a pressure of 140 mm Hg, these features of the novel leaflet design of the present invention allows for faster opening and closing of the valve.
- the side edges 26a illustrate stitch lines along which the body portions 4a, 4b may be stitched to the legs 17 and 18 of the wire frame 102.
- the edges 27a and 27b are attached to the annulus sections 7 and 8 of the wire frame 102.
- the skirt sections 1a and 1b sit on the commissures of the native leaflets along the lines 5.
- the leaflet sections 1a, 1b, 2a and 2b can all be made from treated animal tissue such as pericardium, or from biocompatible polymer material (such as PTFE, Dacron, bovine, porcine, etc.).
- the leaflet sections 1a, 1b, 2a, 2b can also be provided with a drug or bioagent coating to improve performance, prevent thrombus formation, and promote endotheliolization, and can also be treated (or be provided) with a surface layer/coating to prevent calcification.
- FIGS. 6A-6C illustrate the device 100 when it has been deployed at the mitral annulus position in a patient's heart.
- the commissure sections 9 and 10 are seated on the native annulus 22, and each native leaflet 25 is positioned between a gap G1 or G2 which is defined between the tail 131 and the leg 17, and the tail 141 and 18, respectively.
- the bends 13 and 14 of the wire frame 102 are inserted between the chordae and the native leaflets 25 to balance the device 100. This manner of securement allows the device 100 to be securely positioned at the location of the native annulus 22.
- the rounded ends 15 and 16 are positioned under the postero-median commissure (PMC) and artero-lateral commissure (ALC), and the commissure sections 10 and 9 are positioned on the PMC and ALC at the locations 62 and 61, respectively, as shown in FIG. 6D .
- PMC postero-median commissure
- ALC artero-lateral commissure
- This positioning of the device 100 creates a strong anchoring clip effect which prevents the device 100 from moving up and down.
- FIG. 6B shows the leaflet assembly 104 in a closed position
- FIG. 6C shows the leaflet assembly 104 in an opened position
- LA is the left atrium
- LV is the left ventricle
- 25a is the native anterior leaflet
- 25b is the native posterior leaflet
- FIG. 10 shows the valve opened
- FIGS. 1D and IE show the valve closed.
- the device 100 of the present invention can be compacted into a low profile and loaded onto a delivery system, and then delivered to the target location by a non-invasive medical procedure, such as through the use of a delivery catheter through transapical, or transfemoral, or transseptal procedures.
- the mitral valve replacement device can be released from the delivery system once it reaches the target implant site, and can expand to its normal (expanded) profile either by inflation of a balloon (for a balloon expandable supporting structure) or by elastic energy stored in the device (for a device with a self-expandable supporting structure).
- FIGS. 7 and 7A-7E illustrate how the device 100 can be deployed at the mitral annulus of a patient's heart using a transapical delivery system.
- the delivery system has a catheter which has an outer sheath 30 with a distal tip 37.
- a center tube 38 extends through the outer sheath 30 and is connected to the distal tip 37, and a marker band 311 (see FIG. 7A ) is positioned at the distal end of the outer sheath 30.
- 32 indicates the left and right of the marker band 311.
- Two cables 35 and 36 extend through respective tubes 33 and 34, respectively, that run through the interior of the sheath 30.
- FIG. 7A illustrates the device 100 in a collapsed configuration being delivered to the mitral annulus inside the sheath 30.
- the sheath 30 is withdrawn (i.e., moved downwardly) to expose the device so that the self-expanding wire frame 102 will deploy the anterior atrium annulus section 7 and the posterior atrium annulus section 8 in the atrium.
- FIG. 7C the sheath 30 is further withdrawn to release the two cables 35 and 36, and the cables 35 and 36 are detached so that the tails 131 and 141 of the wire frame 102 can be inserted in the chordae under the native commissure leaflet. As shown in FIGS.
- 51a is the anterior leaflet
- 51b is the posterior leaflet
- 52a is the anterior chordae
- 52b is the posterior chordae.
- the annulus sections 7 and 8 "seat” at the mitral annulus area to create a “seal” to prevent leakage (blood flow back from the left ventricle to the left atrium) from the area surrounding the device 100.
- This is best illustrated in FIGS. 6A-6C .
- the opening and closing motion of the valve design of the present invention is very similar to the opening and closing motion of a natural mitral valve.
Description
- The present disclosure is directed to methods, systems, and apparatus for safely replacing or repairing native heart valves with prosthetic heart valves.
- Prosthetic heart valves have been used for many years to treat cardiac valvular disorders. The native heart valves (such as the aortic, pulmonary, and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system. These heart valves can be rendered less effective by congenital, inflammatory, or infectious conditions. Such conditions can eventually lead to serious cardiovascular compromise or death. For many years the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery, but such surgeries are dangerous and prone to complication. Typical prosthetic heart valves are known in the art, for example, patent application publication No.
US2013317603A1 discloses devices and methods for implantation at a native mitral valve having a non-circular annulus and leaflets. Patent application publication No.US2010280606A1 discloses a valve prosthesis adapted to operate in conjunction with native heart valve leaflets, which includes an annulus and a skirt extending from the annulus. Patent application publication No.US2004122513A1 discloses a stentless bioprosthetic valve which includes at least one piece of biocompatible material comprising a bi-leaflet conduit having a proximal end and a distal end. - More recently a transvascular technique has been developed for introducing and implanting a prosthetic heart valve using a flexible catheter in a manner that is less invasive than open heart surgery. In this technique, a prosthetic valve is mounted in a crimped state on the end portion of a flexible catheter and advanced through a blood vessel of the patient until the valve reaches the implantation site. The valve at the catheter tip is then expanded to its functional size at the site of the defective native valve, such as by inflating a balloon on which the valve is mounted. Alternatively, the valve can have a resilient, self-expanding stent or frame that expands the valve to its functional size when it is advanced from a delivery sheath at the distal end of the catheter.
- Unlike the aortic valve, however, the mitral valve annulus does not provide a good landmark for positioning a replacement mitral valve. In patients needing a replacement aortic valve, the height and width of the aortic annulus are generally increased in the presence of degenerative disease associated with calcium formation. These changes in tissue make it easier to properly secure a replacement aortic valve in place due to the reduced cross-sectional area of the aortic annulus. The degenerative changes typically found in aortic valves are not, however, present in mitral valves experiencing regurgitation, and a mitral valve annulus is therefore generally thinner than the annulus of a diseased aortic valve. The thinner mitral valve annulus makes it relatively more difficult to properly seat a replacement mitral valve in the native mitral valve annulus. The general anatomy of the mitral valve annulus also makes it more difficult to properly anchor a replacement mitral valve in place. The mitral valve annulus provides for a smoother transition from the left atrium to the left ventricle than the transition that the aortic valve annulus provides from the aorta to the left ventricle. The aortic annulus is anatomically more pronounced, providing a larger "bump" to which a replacement aortic valve can more easily be secured in place.
- Thus, the larger mitral valve annulus makes it difficult to securely implant current percutaneously delivered valves in the native mitral position. Some attempts have been made to deliver and implant a one-piece replacement mitral valve, but it is difficult to provide a device that can be collapsed down to have a sufficiently small delivery profile and still be able to be expanded and secured in place within the mitral valve via a vascular access site.
- As a result, there remains a need for a replacement mitral valve that has a valve support structure or anchoring device that can be positioned near or within the native mitral valve.
- To accomplish the objectives set forth above, the present invention provides a heart valve assembly that has a leaflet support structure and a leaflet assembly.
- The leaflet support structure has a wire frame having an anterior atrium annulus section and a posterior atrium annulus section, with each opposite end of the atrium annulus sections transitioning to a commissure section that curves radially inwardly along the same plane as the atrium annulus sections. Each commissure section transitions via a first bend to a leg which extends vertically at opposite central points of the wire frame. Each leg extends vertically and slightly radially outwardly at an angle, and each leg transitions via a second bend which extends radially outwardly and transitions into a tail that extends vertically upwardly, with a gap defined between each corresponding tail and leg.
- The leaflet assembly has first and second separate leaflets, each of which is comprised of a skirt section and a sinus leaflet section. Each skirt section has a flange portion and a body portion that has a smaller diameter than the flange portion, with the body portion having opposing side edges, and a curved opening defined by a first stitching edge at about the central portion of the body portion. Each sinus leaflet section has an outflow edge, and a curved second stitching edge, with the sinus leaflet section stitched to the skirt section along the first and second stitching edges. The opposing side edges of the body portion of the first leaflet are stitched to the corresponding side edges of the body portion of the second leaflet. The flange portion has an inflow edge, and a blood flow lumen is defined by the skirt sections and sinus leaflet sections of the first and second leaflets, with the blood flow lumen extending from the inflow edges of the skirt sections to the outflow edges of the sinus leaflet sections.
-
-
FIG. 1 is a perspective view of a mitral valve device according to one embodiment of the present invention. -
FIG. 1A is a schematic side view of the device ofFIG. 1 shown with dimensions according to one non-limiting embodiment thereof, shown with the valve in a naturally open position without any pressure on the leaflets. -
FIG. 1B is a schematic top view of the device ofFIG. 1A shown with dimensions according to one non-limiting embodiment thereof, shown with the valve in a naturally open position without any pressure on the leaflets. -
FIG. 1C is a top view of the device ofFIG. 1 shown with the valve in a fully opened position with pressure on the leaflets. -
FIG. 1D is a top view of the device ofFIG. 1 shown with the valve in a fully closed position with pressure on the leaflets. -
FIG. 1E is a side view of the device ofFIG. 1 shown with the valve in a fully closed position with pressure on the leaflets. -
FIG. 2A is a perspective view of the wire frame of the mitral valve device ofFIG. 1 . -
FIG. 2B is a top view of the wire frame ofFIG. 2A . -
FIG. 2C is a side view of the wire frame ofFIG. 2A . -
FIG. 3A is a perspective conceptual view of the leaflet assembly of the mitral valve design of the device ofFIG. 1 . -
FIG. 3B is a top conceptual view of the leaflet assembly design ofFIG. 3A . -
FIG. 3C is a side conceptual view of the leaflet assembly design ofFIG. 3A . -
FIG. 3D is a conceptual view of the leaflet assembly design ofFIG. 3A . -
FIG. 4A is a perspective view of one embodiment of the leaflet assembly with the tissue of the mitral valve device ofFIG. 1 that is based on the conceptual model shown inFIGS. 3A-3D . -
FIG. 4B is an exploded side view of one of the leaflets of the leaflet assembly ofFIG. 4A . -
FIG. 4C is a side view of the leaflet assembly ofFIG. 4A . -
FIG. 4D is an inside view of one of the leaflets of the leaflet assembly ofFIG. 4A . -
FIG. 4E is an outside view of one of the leaflets of the leaflet assembly ofFIG. 4A . -
FIG. 5A is a top view illustrating the closing of a conventional bileaflet valve assembly using the wire frame ofFIG. 2A . -
FIG. 5B is a perspective view illustrating the closing of a conventional bileaflet valve assembly. -
FIG. 6A is a side view of a patient's heart showing the deployment of the device ofFIG. 1 at the mitral annulus position. -
FIG. 6B is a front view of a patient's heart showing the deployment of the device ofFIG. 1 at the mitral annulus position, with the valve in a closed position. -
FIG. 6C is a front view of a patient's heart showing the deployment of the device ofFIG. 1 at the mitral annulus position, with the valve in an opened position. -
FIG. 6D is a top schematic view of a natural human mitral valve. -
FIG. 7 illustrates a delivery system that can be used to deploy the device ofFIG. 1 . -
FIGS. 7A-7D illustrate how the device ofFIG. 1 can be deployed at the mitral annulus of a patient's heart using a Transapical delivery system. -
FIG. 8 illustrates how the device ofFIG. 1 can be deployed at the mitral annulus of a patient's heart using a (transfemoral or transseptal) percutaneous delivery system. - The following detailed description is of the best presently contemplated modes of carrying out the invention. This description is not to be taken in a limiting sense, but is made merely for the purpose of illustrating general principles of embodiments of the invention. The scope of the invention is best defined by the appended claims.
- The present invention provides a
mitral valve device 100 that is shown in fully assembled form inFIG. 1 . Thedevice 100 has a wire frame 102 (seeFIGS. 2A-2C ) that is adapted to carry an integrated leaflet assembly 104 (seeFIGS. 3A-4D ). Thewire frame 102 provides a simple leaflet valve support structure that can be effectively secured at the native mitral valve annulus. In addition, theleaflet assembly 104 provides a novel leaflet configuration which provides fast opening and closing of the valve leaflets. The overall construction of thedevice 100 is simple, and effective in promoting proper mitral valve function. - As shown in
FIGS. 1-2C , thewire frame 102 comprises an anterioratrium annulus section 7 and a posterioratrium annulus section 8, each of which extends horizontally and is shaped like half an oval. AU-shaped extension section extensions device 100 on the native annulus, and for use in being held by the hooks 191 and 201 of the delivery system (seeFIG. 8 ) during percutaneous delivery. Each opposite end of theatrium annulus sections commissure section atrium annulus sections bends legs wire frame 102. Eachleg FIG. 2C ), and transitions viabends tails tail 131 and theleg 17, and thetail wire frame 102 can define an oval shape (when viewed from the top), a circular shape, or a D shape. -
FIGS. 1A and1B illustrate some exemplary dimensions for thedevice 100 as follows: - D0: 38 mm
- D1: 29 mm
- D2: 34 mm
- D3: 19 mm
- D4: 8 mm
- D5: 24 mm
- H1: 13 mm
- H2: 10 mm
- H3: 2 mm
- L0: 28 mm
- L1: 13 mm
- L2: 19 mm
- L3: 6 mm
- L4: 5 mm
- L5: 29 mm
- L6: 30 mm
- These exemplary dimensions can be used for a
device 100 that is adapted for use at the native mitral valve location for a generic adult and these dimensions will vary fordevices 100 that are used for other applications, such as for a triscupid valve. These exemplary dimensions illustrate the proportions of the various elements to each other. - The
wire frame 102 can be made of one continuous wire, and can be made from a thin wall biocompatible metallic element (such as stainless steel, Co-Cr based alloy, Nitinol™, Ta, and Ti etc.). As an example, the wire can be made from a Nitinol™ wire that is well-known in the art, and have a diameter of 5.08mm to 10.16mm (0.2" to 0.4"). - Referring to
FIGS. 3A through 4D , the present invention provides anovel leaflet assembly 104 that provides a better coaptation between the leaflets. Theleaflet assembly 104 provides two separate leaflets, each of which is comprised of an upper skirt section la or 1b, and a lowersinus leaflet section sections sections FIGS. 4A-4D , theskirt sections semi-oval flange portion diameter body portion body portion side edges 26a that function as commissure folding lines along which theside edges 26a may be stitched to assemble the two separate leaflets into asingle leaflet assembly 104. Eachbody portion edge 29, which is adapted to receive the curved edge of the correspondingsinus leaflet section skirt section - Each
sinus leaflet section outflow edge edge 31. Eachsinus leaflet section stitching edge 31 to thestitching edge 29 of thecorresponding body portion - The construction of the
leaflet assembly 104 provides six components that correspond to the natural six components found in a native mitral valve. For example,FIG. 6D is a top view of a natural mitral valve with six natural components labeled by A1, A2, A3 and P1, P2, P3. Referring now toFIG. 4A , theleaflet assembly 104 has the same six components where 4a, 2a and 4a correspond to A1, A2 and A3, respectively, and 4b, 2b, 4b correspond to P1, P2 and P3, respectively. For this reason, theleaflet assembly 104 is able to function in a manner which comes closest to replicating the natural function of the native mitral valve. - In addition, with the leaflet construction shown in
FIGS. 3A-4D , theleaflet assembly 104 of the present invention provides for a shorter valve assembly which facilitates improved coaptation. For example,FIG. 5A illustrates thewire frame 102 used with a conventional bi-leaflet valve assembly where the two leaflets must necessarily be long enough so as to allow for proper coaptation at the outflow end. In contrast, by sewing thebody portions FIGS. 3A-3C , thesinus leaflet sections outflow edges skirt sections - To illustrate the benefits provided by the novel leaflet assembly shown in
FIGS. 3A-4D , compare the dimensions inFIGS. 1B using the novel leaflet design of the present invention with the dimensions inFIG. 5A for a conventional bi-leaflet valve assembly. InFIG. 1B , the valve design provides a "belly sinus" for a large opening. Using the dimensions inFIG. 1B , when the valve opens, the opening has a width of 35 mm, which is obtained by adding L1 (13 mm)+2×L4 (5 mm)+2×L3 (6 mm)=35 mm. In contrast, the opening provided by a conventional bi-leaflet valve inFIG. 5A would be L0, which is 28 mm. - The novel leaflet design of the present invention allows the valve to open and close faster because a valve with a shorter profile and having the
sinus body portions - Referring also to
FIGS. 1 ,2A-2C and4A-4E , the side edges 26a illustrate stitch lines along which thebody portions legs wire frame 102. In addition, theedges annulus sections wire frame 102. Theskirt sections lines 5. - The
leaflet sections leaflet sections -
FIGS. 6A-6C illustrate thedevice 100 when it has been deployed at the mitral annulus position in a patient's heart. As shown inFIG. 6A , thecommissure sections native annulus 22, and eachnative leaflet 25 is positioned between a gap G1 or G2 which is defined between thetail 131 and theleg 17, and thetail bends wire frame 102 are inserted between the chordae and thenative leaflets 25 to balance thedevice 100. This manner of securement allows thedevice 100 to be securely positioned at the location of thenative annulus 22. In particular, the rounded ends 15 and 16 are positioned under the postero-median commissure (PMC) and artero-lateral commissure (ALC), and thecommissure sections locations FIG. 6D . This positioning of thedevice 100 creates a strong anchoring clip effect which prevents thedevice 100 from moving up and down. -
FIG. 6B shows theleaflet assembly 104 in a closed position, andFIG. 6C shows theleaflet assembly 104 in an opened position, where LA is the left atrium, and LV is the left ventricle. 25a is the native anterior leaflet, and 25b is the native posterior leaflet. FIG. 10 shows the valve opened, whileFIGS. 1D and IE show the valve closed. - The
device 100 of the present invention can be compacted into a low profile and loaded onto a delivery system, and then delivered to the target location by a non-invasive medical procedure, such as through the use of a delivery catheter through transapical, or transfemoral, or transseptal procedures. The mitral valve replacement device can be released from the delivery system once it reaches the target implant site, and can expand to its normal (expanded) profile either by inflation of a balloon (for a balloon expandable supporting structure) or by elastic energy stored in the device (for a device with a self-expandable supporting structure). -
FIGS. 7 and7A-7E illustrate how thedevice 100 can be deployed at the mitral annulus of a patient's heart using a transapical delivery system. Referring first toFIG. 7 , the delivery system has a catheter which has anouter sheath 30 with adistal tip 37. Acenter tube 38 extends through theouter sheath 30 and is connected to thedistal tip 37, and a marker band 311 (seeFIG. 7A ) is positioned at the distal end of theouter sheath 30. 32 indicates the left and right of themarker band 311. Twocables respective tubes sheath 30.FIG. 7A illustrates thedevice 100 in a collapsed configuration being delivered to the mitral annulus inside thesheath 30. InFIG. 7B , thesheath 30 is withdrawn (i.e., moved downwardly) to expose the device so that the self-expandingwire frame 102 will deploy the anterioratrium annulus section 7 and the posterioratrium annulus section 8 in the atrium. InFIG. 7C , thesheath 30 is further withdrawn to release the twocables cables tails wire frame 102 can be inserted in the chordae under the native commissure leaflet. As shown inFIGS. 7A-7D , 51a is the anterior leaflet, 51b is the posterior leaflet, 52a is the anterior chordae and 52b is the posterior chordae. Once this occurs, thedevice 100 is deployed at the native annulus, and inFIG. 7d , the delivery system can be withdrawn. - Thus, when the
device 100 is deployed, theannulus sections device 100. This is best illustrated inFIGS. 6A-6C . In addition, the opening and closing motion of the valve design of the present invention is very similar to the opening and closing motion of a natural mitral valve.
Claims (12)
- A leaflet assembly (104) for use with a prosthetic heart valve, comprising:first and second separate leaflets, each of which is comprised of:a skirt section (1a, 1b) having a flange portion (6a, 6b) and a body portion (4a, 4b) that has a smaller diameter than the flange portion (6a, 6b), the body portion (4a, 4b) has opposing side edges (26a), and a curved opening defined by a first stitching edge (29) at about the central portion of the body portion (4a, 4b); anda sinus leaflet section (2a, 2b) having an outflow edge (3a, 3b), and a curved second stitching edge (31), with the sinus leaflet section (2a, 2b) stitched to the skirt section (1a, 1b) along the first (29) and second stitching edges (31)wherein the opposing side edges (26a) of the body portion (4a, 4b) of the first leaflet are stitched to the corresponding side edges (26a) of the body portion (4a, 4b) of the second leaflet;characterized in that, the flange portion (6a, 6b) has an inflow edge, and a blood flow lumen is defined by the skirt sections (1a, 1b) and sinus leaflet sections (2a, 2b) of the first and second leaflets, with the blood flow lumen extending from the inflow edges of the skirt sections (1a, 1b) to the outflow edges (3a, 3b) of the sinus leaflet sections (2a, 2b).
- The leaflet assembly (104) of claim 1, wherein each flange portion (6a, 6b) has a semi-oval shape.
- The leaflet assembly (104) of claim 1, wherein the curved opening is U-shaped.
- The leaflet assembly (104) of claim 1, wherein each sinus leaflet section (2a, 2b) has a generally semi-circular shape.
- A heart valve assembly (100), comprising:a leaflet support structure that comprises a wire frame (102) having an anterior atrium annulus section (7) and a posterior atrium annulus section (8), with each opposite end of the atrium annulus sections (7, 8) transitioning to a commissure section (9, 10) that curves radially inwardly along the same plane as the atrium annulus sections (7, 8), and which then transitions via a first bend (11, 12) to a leg (17, 18) which extends vertically at opposite central points of the wire frame (102), each leg (17, 18) extending vertically and slightly radially outwardly at an angle, and each leg (17, 18) transitioning via a second bend (13, 14) which extends radially outwardly and transitions into a tail (131, 141) that extends vertically upwardly, with a gap (G1, G2) defined between each corresponding tail (131, 141) and leg (17, 18); anda leaflet assembly (104) having first and second separate leaflets that are stitched to the legs (17, 18) and the atrium annulus sections (7, 8) of the wire frame (102), characterized in that, each leaflet is comprised of:a skirt section (1a, 1b) having a flange portion (6a, 6b) and a body portion (4a, 4b) that has a smaller diameter than the flange portion (6a, 6b), the flange portion (6a, 6b) having an inflow edge, the body portion (4a, 4b) has opposing side edges (26a), and a curved opening defined by a first stitching edge (29) at about the central portion of the body portion (4a, 4b); anda sinus leaflet section (2a, 2b) having an outflow edge (3a, 3b), and a curved second stitching edge (31), with the sinus leaflet section (2a, 2b) stitched to the skirt section (1a, 1b) along the first (29) and second stitching edges (31)wherein the opposing side edges (26a) of the body portion (4a, 4b) of the first leaflet are stitched to the corresponding side edges (26a) of the body portion (4a, 4b) of the second leaflet; andwherein a blood flow lumen is defined by the skirt sections (1a, 1b) and sinus leaflet sections (2a, 2b) of the first and second leaflets, with the blood flow lumen extending from the inflow edges of the skirt sections (1a, 1b) to the outflow edges (3a, 3b) of the sinus leaflet sections (2a, 2b).
- The assembly of claim 5, wherein each atrium annulus section (7, 8) extends horizontally and is shaped like half an oval.
- The assembly of claim 5, wherein an extension (19, 20) is provided at about the central portion of each atrium annulus section (7, 8) and extends radially outwardly.
- The assembly of claim 5, wherein the wire frame (102) defines a shape selected from the group consisting of: an oval shape, a circular shape, and a D shape.
- The assembly of claim 5, wherein each tail (131, 141) terminates at a rounded end (15, 16) which curves radially outwardly.
- The assembly of claim 5, wherein each flange portion (6a, 6b) has a semi-oval shape.
- The assembly of claim 5, wherein the curved opening is U-shaped.
- The assembly of claim 5, wherein each sinus leaflet section (2a, 2b) has a generally semi-circular shape.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/595,433 US9579195B2 (en) | 2015-01-13 | 2015-01-13 | Mitral bileaflet valve |
PCT/US2015/068020 WO2016114928A1 (en) | 2015-01-13 | 2015-12-30 | Mitral bileaflet valve |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3244834A1 EP3244834A1 (en) | 2017-11-22 |
EP3244834A4 EP3244834A4 (en) | 2018-08-01 |
EP3244834B1 true EP3244834B1 (en) | 2020-11-04 |
Family
ID=56366686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15878296.1A Active EP3244834B1 (en) | 2015-01-13 | 2015-12-30 | Mitral bileaflet valve |
Country Status (4)
Country | Link |
---|---|
US (2) | US9579195B2 (en) |
EP (1) | EP3244834B1 (en) |
CN (1) | CN107205816B (en) |
WO (1) | WO2016114928A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11311376B2 (en) | 2019-06-20 | 2022-04-26 | Neovase Tiara Inc. | Low profile prosthetic mitral valve |
US11357622B2 (en) | 2016-01-29 | 2022-06-14 | Neovase Tiara Inc. | Prosthetic valve for avoiding obstruction of outflow |
US11389291B2 (en) | 2013-04-04 | 2022-07-19 | Neovase Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US11389294B2 (en) | 2012-05-30 | 2022-07-19 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US11413139B2 (en) | 2011-11-23 | 2022-08-16 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11419720B2 (en) | 2010-05-05 | 2022-08-23 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US11464631B2 (en) | 2016-11-21 | 2022-10-11 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
US11491006B2 (en) | 2019-04-10 | 2022-11-08 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
US11497602B2 (en) | 2012-02-14 | 2022-11-15 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US11602429B2 (en) | 2019-04-01 | 2023-03-14 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
US11737872B2 (en) | 2018-11-08 | 2023-08-29 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
US11779742B2 (en) | 2019-05-20 | 2023-10-10 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
US11793640B2 (en) | 2017-08-25 | 2023-10-24 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9011515B2 (en) | 2012-04-19 | 2015-04-21 | Caisson Interventional, LLC | Heart valve assembly systems and methods |
US9427315B2 (en) | 2012-04-19 | 2016-08-30 | Caisson Interventional, LLC | Valve replacement systems and methods |
US9050188B2 (en) | 2013-10-23 | 2015-06-09 | Caisson Interventional, LLC | Methods and systems for heart valve therapy |
US9974647B2 (en) | 2014-06-12 | 2018-05-22 | Caisson Interventional, LLC | Two stage anchor and mitral valve assembly |
US9750607B2 (en) | 2014-10-23 | 2017-09-05 | Caisson Interventional, LLC | Systems and methods for heart valve therapy |
US9750605B2 (en) | 2014-10-23 | 2017-09-05 | Caisson Interventional, LLC | Systems and methods for heart valve therapy |
EP3307207A1 (en) | 2015-06-12 | 2018-04-18 | St. Jude Medical, Cardiology Division, Inc. | Heart valve repair and replacement |
GB2539444A (en) | 2015-06-16 | 2016-12-21 | Ucl Business Plc | Prosthetic heart valve |
US9895222B2 (en) * | 2015-08-17 | 2018-02-20 | Venus Medtech (Hangzhou) Inc. | Aortic replacement valve |
US10456243B2 (en) * | 2015-10-09 | 2019-10-29 | Medtronic Vascular, Inc. | Heart valves prostheses and methods for percutaneous heart valve replacement |
WO2017117388A1 (en) | 2015-12-30 | 2017-07-06 | Caisson Interventional, LLC | Systems and methods for heart valve therapy |
GB2557238A (en) * | 2016-08-12 | 2018-06-20 | Flugelman Moshe | Personalised mitral valve assembly |
US10653523B2 (en) | 2017-01-19 | 2020-05-19 | 4C Medical Technologies, Inc. | Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves |
US10561495B2 (en) | 2017-01-24 | 2020-02-18 | 4C Medical Technologies, Inc. | Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve |
US11666444B2 (en) | 2017-08-03 | 2023-06-06 | The Regents Of The University Of California | Atrial cage for placement, securing and anchoring of atrioventricular valves |
US10722353B2 (en) | 2017-08-21 | 2020-07-28 | Edwards Lifesciences Corporation | Sealing member for prosthetic heart valve |
CN111601638A (en) * | 2018-02-22 | 2020-08-28 | 美国政府(由卫生和人类服务部的部长所代表) | Internal bending charge concentrator for tissue tearing |
CN108814771B (en) * | 2018-03-05 | 2020-02-21 | 何铭权 | Two-leaf biological valve |
US11857441B2 (en) | 2018-09-04 | 2024-01-02 | 4C Medical Technologies, Inc. | Stent loading device |
US11931253B2 (en) | 2020-01-31 | 2024-03-19 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3739402A (en) * | 1970-10-15 | 1973-06-19 | Cutter Lab | Bicuspid fascia lata valve |
GB8300636D0 (en) * | 1983-01-11 | 1983-02-09 | Black M M | Heart valve replacements |
IT1245750B (en) * | 1991-05-24 | 1994-10-14 | Sorin Biomedica Emodialisi S R | CARDIAC VALVE PROSTHESIS, PARTICULARLY FOR REPLACING THE AORTIC VALVE |
AU2003282616B2 (en) * | 2002-10-10 | 2006-06-29 | The Cleveland Clinic Foundation | Method and apparatus for replacing a mitral valve with a stentless bioprosthetic valve |
US20050149181A1 (en) * | 2004-01-07 | 2005-07-07 | Medtronic, Inc. | Bileaflet prosthetic valve and method of manufacture |
US8349001B2 (en) * | 2004-04-07 | 2013-01-08 | Medtronic, Inc. | Pharmacological delivery implement for use with cardiac repair devices |
US7914569B2 (en) * | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
WO2010106438A2 (en) * | 2009-03-17 | 2010-09-23 | Biomedxl | Heart valve prosthesis with collapsible valve and method of delivery thereof |
AU2012272855C1 (en) * | 2011-06-21 | 2018-04-05 | Twelve, Inc. | Prosthetic heart valve devices and associated systems and methods |
US8603162B2 (en) * | 2011-07-06 | 2013-12-10 | Waseda University | Stentless artificial mitral valve |
US10016271B2 (en) * | 2011-10-19 | 2018-07-10 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US9039757B2 (en) * | 2011-10-19 | 2015-05-26 | Twelve, Inc. | Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods |
US20130310927A1 (en) * | 2012-05-18 | 2013-11-21 | James Quintessenza | Implantable Valve System |
US9872765B2 (en) * | 2015-10-12 | 2018-01-23 | Venus Medtech (Hangzhou) Inc | Mitral valve assembly |
-
2015
- 2015-01-13 US US14/595,433 patent/US9579195B2/en active Active
- 2015-12-30 WO PCT/US2015/068020 patent/WO2016114928A1/en active Application Filing
- 2015-12-30 CN CN201580073286.9A patent/CN107205816B/en active Active
- 2015-12-30 EP EP15878296.1A patent/EP3244834B1/en active Active
-
2017
- 2017-02-07 US US15/426,935 patent/US9895220B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11419720B2 (en) | 2010-05-05 | 2022-08-23 | Neovasc Tiara Inc. | Transcatheter mitral valve prosthesis |
US11413139B2 (en) | 2011-11-23 | 2022-08-16 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11497602B2 (en) | 2012-02-14 | 2022-11-15 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US11389294B2 (en) | 2012-05-30 | 2022-07-19 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US11617650B2 (en) | 2012-05-30 | 2023-04-04 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US11389291B2 (en) | 2013-04-04 | 2022-07-19 | Neovase Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
US11357622B2 (en) | 2016-01-29 | 2022-06-14 | Neovase Tiara Inc. | Prosthetic valve for avoiding obstruction of outflow |
US11464631B2 (en) | 2016-11-21 | 2022-10-11 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
US11793640B2 (en) | 2017-08-25 | 2023-10-24 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11737872B2 (en) | 2018-11-08 | 2023-08-29 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
US11602429B2 (en) | 2019-04-01 | 2023-03-14 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
US11491006B2 (en) | 2019-04-10 | 2022-11-08 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
US11779742B2 (en) | 2019-05-20 | 2023-10-10 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
US11311376B2 (en) | 2019-06-20 | 2022-04-26 | Neovase Tiara Inc. | Low profile prosthetic mitral valve |
US11931254B2 (en) | 2019-06-20 | 2024-03-19 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
Also Published As
Publication number | Publication date |
---|---|
US20170143486A1 (en) | 2017-05-25 |
WO2016114928A1 (en) | 2016-07-21 |
CN107205816B (en) | 2019-05-21 |
EP3244834A1 (en) | 2017-11-22 |
US9895220B2 (en) | 2018-02-20 |
EP3244834A4 (en) | 2018-08-01 |
CN107205816A (en) | 2017-09-26 |
US20160199180A1 (en) | 2016-07-14 |
US9579195B2 (en) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3244834B1 (en) | Mitral bileaflet valve | |
US10543082B2 (en) | Heart valve assembly | |
US11833038B2 (en) | Valve prosthesis and method for delivery | |
CN108156805B (en) | Mitral valve assembly | |
CN107787209B (en) | Percutaneous mitral valve replacement device | |
AU2015221440B2 (en) | A replacement valve | |
US10098733B2 (en) | Expandable prosthetic valve having anchoring appendages | |
JP2023184533A (en) | Prosthetic leaflet device | |
JP7087092B2 (en) | Expandable frame and perivalvular leak mitigation system for implantable prosthetic valve devices | |
JP2019500994A (en) | Implants and methods for improving atrioventricular valve bonding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180703 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 2/24 20060101AFI20180627BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200423 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VENUS MEDTECH (HANGZHOU), INC. |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1329848 Country of ref document: AT Kind code of ref document: T Effective date: 20201115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015061687 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1329848 Country of ref document: AT Kind code of ref document: T Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210204 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015061687 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20201231 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20210805 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201230 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201230 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210304 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201104 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20221222 Year of fee payment: 8 Ref country code: FR Payment date: 20221222 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20230104 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231220 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231214 Year of fee payment: 9 |